Board of Directors

Mark H.N. Corrigan, M.D.

Dr. Corrigan has served as President and Chief Executive Officer Since January 2010. Dr. Corrigan joined U.S.-based specialty pharmaceutical company Sepracor Inc. in 2003 and served as their Executive Vice President, Research & Development until December 2009. Prior to joining Sepracor Inc., Dr. Corrigan spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Dr. Corrigan has been a member of the board of directors and the audit committee of Cubist Pharmaceuticals, Inc. since 2008. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center. Back to Top

Sally W. Crawford

From April 1985 until January 1997, Ms. Crawford served as Chief Operating Officer of Healthsource, Inc., a publicly held managed care organization headquartered in New Hampshire. During her tenure at Healthsource, Inc., Ms. Crawford held a variety of positions and responsibilities, including leading that company’s Northern Region operations and marketing efforts. Since January 1997, Ms. Crawford has been a healthcare consultant in New Hampshire. Ms. Crawford serves on the board of directors for Hologic, Inc., Exact Sciences Corporation, Insulet Corporation and Universal American Corp. Ms. Crawford holds a B.A. in English from Smith College and an M.S. in communications from Boston University. Back to Top

Todd Foley

Mr. Foley is currently a Managing Director at MPM Asset Management LLC, or MPM. Since joining MPM in 1999, Mr. Foley has been actively involved in numerous investments including a part-time engagement as Chief Operating Officer for Centagenetix Inc. during its start-up phase and VP, Business Development for AVEO Pharmaceuticals, Inc. Prior to joining MPM, Mr. Foley worked in Business Development at Genentech, Inc. and management consulting with Arthur D. Little. Mr. Foley holds a B.S. in Chemistry from MIT and an M.B.A. from Harvard Business School. Back to Top

Christopher C. Gallen, M.D., Ph.D.

Dr. Gallen has served as Executive Vice President of Research and Development since January 2010. Dr. Gallen served as the President and Chief Executive Officer of Neuromed from July 2004 to December 2009. Prior to joining Neuromed, Dr. Gallen worked for Wyeth Research beginning in April 2002 and most recently served as its Vice President and Chief of Operations, Clinical Research and Development. Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia Corporation for three years. From January 1996 to December 1998, Dr. Gallen was the President of the Clinical Research Organization division at Premier Research Worldwide and from 1994 to 1995 he was the Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation. Dr. Gallen holds a B.A. from the University of Florida, and an M.D. and Ph.D. from Emory University School of Medicine in Atlanta, Georgia and trained in Psychiatry at Stanford and Neurology at the University of California, San Diego. Back to Top

Frank Haydu

(Chairman)
Mr. Haydu has served as Chairman of the CombinatoRx board of directors since February 2009. Since 2001, Mr. Haydu has been the Managing Director of Valuation Perspectives, Inc., a financial services consulting practice and has served in a consulting capacity at Source Precision Medicine, a life sciences medical supplier, since August 2005. Until May 2001, Mr. Haydu served as the Chairman of Haydu & Lind, LLC, a senior living development company. Mr. Haydu serves on the board of directors for iParty Corp. Mr. Haydu holds a B.A. in economics from Muhlenberg College. Back to Top

Bill Hunter, M.D.

Dr. Hunter founded Angiotech Pharmaceuticals, Inc. in November 1992 and has most recently served as its President & Chief Executive Officer. Dr. Hunter serves as the chair of the board for Neuromed Pharmaceuticals and as a director for Cardiome Pharma Corp. Dr. Hunter holds a B.Sc. from McGill University, and an M.Sc. and M.D. from the University of British Columbia. Back to Top

Michael G. Kauffman, M.D.

Dr. Kauffman has been the Chief Medical Officer of Onyx Pharmaceuticals since January 2010, after serving on an interim basis beginning in November 2009, and has been an Operating Partner at Bessemer Venture Partners since 2008. Dr. Kauffman was the Chief Medical Officer of Proteolix, Inc. from April 2009 until November 2009 and was the President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. until July 2008. Dr. Kauffman joined Predix Pharmaceuticals, Inc., the predecessor to EPIX, in September 2002, as President and Chief Executive Officer. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., including Vice President, Medicine and VELCADE Program Leader as well as co-founder and Vice President of Medicine at Millennium Predictive Medicine, a wholly-owned subsidiary of Millennium. Dr. Kauffman also served as Medical Director at Biogen Corporation (now Biogen Idec). Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins and holds a B.A. in biochemistry from Amherst College. Dr. Kauffman trained in Internal Medicine at Beth Israel Deaconess and Massachusetts General Hospitals. He is board certified in internal medicine. Back to Top

W. James O'Shea

From October 1999 to March 2007, Mr. O'Shea was President and Chief Operating Officer at Sepracor Inc. where he was responsible for successfully building that organization's commercial infrastructure. From April to August 2007, Mr. O'Shea served as Sepracor's Vice Chairman. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Zeneca Inc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing in the U.S. and U.K. Mr. O'Shea is past Chairman of the National Pharmaceutical Council and is also a board member of BTG plc. Mr. O'Shea is a graduate of Liverpool Lord Byron University. He also received an honors degree in applied physics from the Institute of Physics.Back to Top

Hartley T. Richardson

Mr. Richardson has been President and Chief Executive Officer of James Richardson & Sons, Limited since 1993. Mr. Richardson serves as a Director of Canadian Pacific Railway and is a Director and Past-Chairman of the Business Council of Manitoba and Vice-Chairman of the Canadian Council of Chief Executives. In addition, Mr. Richardson is Chairman of Assiniboine Park Conservancy, Vice Chairman of TransCanada Trail, and member of the Board of Governors for the Duke of Edinburgh’s Award. Other affiliations include the Trilateral Commission, the World Economic Forum Global Leaders of Tomorrow, and the Young President’s Organization. Mr. Richardson holds a Bachelor of Commerce (Honours) and an Honorary Doctor of Laws from the University of Manitoba. Back to Top